This phase I trial studies how well an imaging tracer agent (PSMA-targeting C’ dots) works for the detection of prostate cancer. PSMA-targeting C’ dots is an imaging tracer agent targeted to the protein PSMA (prostate-specific membrane antigen), which is located only on prostate cancer cells. PET/MRI scans done after an injection of PSMA-targeting C’ dots may detect PSMA proteins more precisely than other imaging test. PSMA-targeting C’ dots tracer may help surgeons locate prostate cancer cells more accurately before and during surgery and improve diagnosis and treatment of prostate cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT04167969.
Locations matching your search criteria
United States
New York
New York
Memorial Sloan Kettering Cancer CenterStatus: Active
Contact: Karim A. Touijer
Phone: 646-422-4486
PRIMARY OBJECTIVES:
I. Conduct single-dose studies of dual-modality prostate-specific membrane antigen (PSMA)-targeting C’ dots (89 Zirconium [Zr]-DFO-PSMA-PEGCy5.5-C’ and copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots [64Cu-NOTA-PSMAPEG-Cy5.5-C’ dots]) to characterize safety, biodistribution/pharmacokinetics, and dosimetry in patients with high-risk prostate cancer using pre-operative positron emission tomography (PET)/magnetic resonance (MR) imaging.
II. Assay particle distributions in prostate tumor tissue and nodal tissue before and after surgery using image-guided intraoperative optical imaging and histologic analyses, including autoradiography and fluorescence microscopy.
SECONDARY OBJECTIVES:
I. Estimate the proportion of patients with localized lymph nodes and residual tumor along surgical margins with intraoperative optical imaging using the fluorescence signal of PSMA-targeting C’ dots.
II. Determine the diagnostic accuracy of PSMA-targeting C’ dots in detecting prostate cancer in primary and metastatic lymph nodes (LNs) using whole-mount step section pathologic analysis as the reference standard.
OUTLINE:
Patients receive PSMA-targeting C’ dots intravenously (IV) over 1 minute. Patients then undergo positron emission tomography (PET)/magnetic resonance imaging (MRI) scan over 1 hour at 1, 4, and 24 hours after injection. Within 24 hours of the third PET/MRI scan, patient undergo standard of care laparoscopic radical prostatectomy and bilateral pelvic LN dissection.
After completion of study, patients are followed up at 30 days.
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorKarim A. Touijer